Greater China News
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
Henlius successfully held its first Overseas Scientific Advisory Board (SAB) meeting of 2023 in California, United States.
Burning Rock Announces Resignation and Appointment of Directors
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) announced the resignation of Dr. Shaokun (Shannon) Chuai as a director from the board of directors and as the Company’s Chief Scientific Officer, effective June 30, 2023.
Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company
Shineco, Inc. (NASDAQ: SISI), announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd. to establish a joint venture company, Shangkang Life Science and Technology.
Aurisco gets Auxiton® (Dydrogesterone) as first generic approval in China
Aurisco Pharmaceutical received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA.
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, announced that Xuanzhu Biopharmaceutical Co. received a drug registration approval from China's NMPA of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,312.5 million (or US$42.3 million at FX=31).
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it entered into definitive agreements with Qpex Biopharma ("Qpex") and third parties in connection with the acquisition of Qpex by Shionogi.
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
DAEJEON, South Korea, June 19, 2023 /PRNewswire/ -- Curocell Inc, a Korea-based clinical-stage CAR-T cell therapy company, announced updated Phase 2 interim results for Anbalcabtagene-autoleucel (anbal-cel) on June 15, 2023, at ICML (International Conference on Malignant Lymphoma), Lugano, Switzerland.
RevolKa Ltd.: Announcement of Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd.
TOKYO--(BUSINESS WIRE)--RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Shiro Kataoka, CEO) is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd.
